Gene expression based inference of cancer drug sensitivity
Predictive modeling approach to infer treatment response in cancers.
The cancer Digital Twin Agent designed for the point of care.
CANCER THERAPY SIMULATION BEFORE A SINGLE DOSE
A new decision-support tool for oncologists and hospitals. A molecular replica of each patient’s tumor simulating how it responds, resists, and evolves.
Tests give data. Guidelines give rules. Neither tells you what works for this patient.
0%
FIRST THERAPY FAILURE
Nearly 1 in 3 patients endure an ineffective first therapy.
0%
RESISTANCE-LINKED DEATHS
Most cancer deaths trace back to drug resistance.
0K+
NEW PAPERS PER YEAR
No oncologist can keep pace with the literature.
0K+
CANCER TEST TYPES
Each generates data. None tells you what to do with it.
Continuous cancer care intelligence now becomes essential.
Navigating Cancer Care together.
Oncology AI agents designed for for every step of the Patient journey
Casebook
AI-native clinical EHR. Six specialized agents. Any test ingested.
MyCasebook
The patient’s AI co-pilot. Genomic data in plain language.
Digital Twin
Molecular cancer therapy simulation. Every treatment ranked.
Deep Precision NGS™
Cancer sequencing panels, built for the Digital Twin.
GS Clinica
AI-first CRO platform with patient and CRO data sets, AI analytics and integrations.
The AI-First Cancer Center
Oncology elevated to a new standard
GeneSilico pairs an AI agent with every role in your cancer center, unified under one Oncology Clinical Control Plane, delivering precision care personalized to every patient, with radical efficiency at a fraction of the cost.
Cancer AI
Oncologist | Surgeon
AI Casebook
Tumor Board
Deep Precision NGS
Onco Pathologist
Digital Twin
Oncologist | Board
Lab Agent
Haematologist
MyCasebook
Physician’s Assistant
Partner Connect
Radiologist
Super efficiency
every role, top of license
Precision Care
personalized to each patient
Lower cost
per episode of care
~2hrs
Specialist time returned per role, per day
Days → hrs
From biopsy to actionable plan
-25%
Cost per episode of care
+3×
Therapy & trial matches surfaced
The gSageTM Platform Trustworthy cancer AI proves, explains, and governs every decision.
One secure, governed platform beneath every point of care.
gSage helps anticipate challenges and navigate decisions
Simulate response before the first dose rather than after several lines of therapy.
Models molecular changes that may signal emerging resistance.
Pharmacogenomic flags surface risk before it reaches the patient.
Next-line options modeled now, ready the moment they’re needed.
GAP tags surface what to order before it’s needed, UG- T1A1 before sacituzumab, HbA1c before alpelisib, ranked.
Therapies Ranked by Digital Twin Simulation
Patient #4471
Regimen A
0%Regimen B
0%Regimen C
0%● Resistance model flagged and deprioritized
FOR BIG PHARMA AND AI DRUG DISCOVERY UPSTARTS” – AI FIRST PATIENT DRUG EFFICACY VALIDATION AT POINT OF CARE.
From molecule to patient evidence.
GeneSilico closes the gap between AI drug discovery and human proof, generating efficacy evidence continuously across an oncology hospital and CRO network for AI-native biotech and pharma.
Molecule
An AI-discovered candidate, ready for human proof.
Digital Twin
Response modeled patient by patient, before a dose.
Real-time trial
Multicentre study across the hospital and CRO network.
Efficacy evidence
Structured, auditable evidence to sponsors and regulators.
ARTICLES
Join us in the fight
against cancer
Live with hundreds of oncologists. Ready for your institution